Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

Lièvre, 2020, Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid patients with cancer and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19), Eur J Cancer, 141, 62, 10.1016/j.ejca.2020.09.035 Whisenant, 2020, TERAVOLT: thoracic cancers international COVID-19 collaboration, Cancer Cell, 37, 742, 10.1016/j.ccell.2020.05.008 Garassino, 2020, COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, Lancet Oncol, 21, 914, 10.1016/S1470-2045(20)30314-4 Zhang, 2020, Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China, Ann Oncol, 31, 894, 10.1016/j.annonc.2020.03.296 Dai, 2020, Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak, Cancer Discov, 10, 783, 10.1158/2159-8290.CD-20-0422 Yang, 2020, Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study, Lancet Oncol, 21, 904, 10.1016/S1470-2045(20)30310-7 Onder, 2020, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA, 323, 1775 Levin, 2020, Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications, Eur J Epidemiol, 35, 1123, 10.1007/s10654-020-00698-1 Meyerowitz-Katz, 2020, A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates, Int J Infect Dis, 101, 138, 10.1016/j.ijid.2020.09.1464 Mi, 2020, Estimating the instant case fatality rate of COVID-19 in China, Int J Infect Dis, 97, 1, 10.1016/j.ijid.2020.04.055 Hawkins, 2020, Socio-economic status and COVID-19-related cases and fatalities, Public Health, 189, 29, 10.1016/j.puhe.2020.09.016 Rondy, 2017, 2015/15 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project, Euro Surveill, 22, 30580, 10.2807/1560-7917.ES.2017.22.30.30580 Hottinger, 2012, A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients, Oncologist, 17, 436, 10.1634/theoncologist.2011-0342 Beck, 2012, J Infect Dis, 206, 1250, 10.1093/infdis/jis487 Bersanelli, 2021, INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2), J Immunother Cancer, 9 Polack, 2020, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N Engl J Med, 383, 2603, 10.1056/NEJMoa2034577 Jackson, 2020, An mRNA vaccine against SARS-CoV-2—preliminary report, N Engl J Med, 383, 1920, 10.1056/NEJMoa2022483 Baden, 2020, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N Engl J Med, 384, 403, 10.1056/NEJMoa2035389 Sadoff, 2021, Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19, N Engl J Med, 384, 2187, 10.1056/NEJMoa2101544 Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 Voysey, 2021, Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials, Lancet, 397, 881, 10.1016/S0140-6736(21)00432-3 Milman, 2021, Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals, Nat Med, 27, 1367, 10.1038/s41591-021-01407-5 Vasileiou, 2021, Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study, Lancet, 397, 1646, 10.1016/S0140-6736(21)00677-2 Widge, 2020, Durability of responses after SARS-CoV-2 mRNA-1273 vaccination, N Engl J Med, 384, 80, 10.1056/NEJMc2032195 Robertson, 2021, Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?, Lancet, 397, 879, 10.1016/S0140-6736(21)00455-4 Kadire, 2021, Delayed Second Dose versus Standard Regimen for COVID-19 Vaccination, N Engl J Med, 384, e28, 10.1056/NEJMclde2101987 Castells, 2021, Maintaining safety with SARS-CoV-2 vaccines, N Engl J Med, 384, 643, 10.1056/NEJMra2035343 Kertes Luo, 2020, COVID-19 in patients with lung cancer, Ann Oncol, 31, 1386, 10.1016/j.annonc.2020.06.007 Di Noia, 2021, The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: early data from a single-institute survey, Eur J Cancer, 153, 260.e4, 10.1016/j.ejca.2021.05.006 Waissengrin, 2021, Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors, Lancet Oncol, 22, 581, 10.1016/S1470-2045(21)00155-8 Addeo, 2021, Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer, Cancer Cell, 39, 1, 10.1016/j.ccell.2021.06.009 Palich, 2021, Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients, Ann Oncol, 32, 1051, 10.1016/j.annonc.2021.04.020 Khoury, 2021, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat Med, 27, 1205, 10.1038/s41591-021-01377-8 Alizon, 2021, Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021, Euro Surveill, 26, 2100573, 10.2807/1560-7917.ES.2021.26.28.2100573 Davies, 2021, Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England, Science, 372, eabg3055, 10.1126/science.abg3055 Jones, 2021, Estimating infectiousness throughout SARS-CoV-2 infection course, Science, 373, eabi5273, 10.1126/science.abi5273 Kidd, 2021, S variant SARS CoV 2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by Thermo Fisher TaqPath RT qPCR, J Infect Dis, 223, 1666, 10.1093/infdis/jiab082 Turner, 2021, SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses, Nature, 596, 109, 10.1038/s41586-021-03738-2 Tober-Lau, 2021, Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers., Lancet Respir Med, 9, E104, 10.1016/S2213-2600(21)00456-2 Collier, 2021, Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2, Nature, 596, 417, 10.1038/s41586-021-03739-1 Iacono, 2021, Serological response to COVID-19 vaccination in patients with cancer older than 80 years, J Geriatr Oncol, 12, 1253, 10.1016/j.jgo.2021.06.002 Barriere, 2021, Impaired immunogenicity of BNT162b2 anti SARS-CoV-2 vaccine in patients treated for solid tumors, Ann Oncol, 32, 1053, 10.1016/j.annonc.2021.04.019 Massarweh, 2021, Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer, JAMA Oncol, 7, 1133, 10.1001/jamaoncol.2021.2155 Gavriatopoulou, 2021, Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine, Clin Exp Med, 234, 1 Boyarsky, 2021, Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients, JAMA, 325, 2204, 10.1001/jama.2021.7489 Lim, 2021, Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma, Lancet Haematol, 8, e542, 10.1016/S2352-3026(21)00199-X Herishanu, 2021, Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic Lymphocyti leukemia, Blood, 137, 3165, 10.1182/blood.2021011568 Van Oekelen, 2021, Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma, Cancer Cell, 39, 1028, 10.1016/j.ccell.2021.06.014 Kamar, 2021, Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients, N Engl J Med, 385, 661, 10.1056/NEJMc2108861